All In Biotech

Drug Trial Radar · NCT06579092

Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity

A Phase IIb Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD5004 in Participants Living With Obesity or Overweight With Comorbidity

Last checked: Nov 19, 2026Latest source record: Dec 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 310 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

310

Actual

Start

Oct 8, 2024

Primary completion

Nov 21, 2025

Study completion Nov 21, 2025

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Aug 30, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase IIb, global, randomized, parallel-group, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of AZD5004 compared with placebo, given once daily as an oral tablet(s) for 36 weeks, in male and female participants at least 18 years of age who are living with obesity (body mass index \[BMI\] ≥ 30 kg/m2), or overweight (BMI ≥ 27 kg/m2) who have at least 1 weight-related comorbidity

Conditions

  • Obesity or Overweight

Interventions

  • AZD5004Drug

    AZD5004 film-coated tablet once daily during 36 weeks

  • PlaceboDrug

    Placebo matching AZD5004 film-coated tablet once daily during 36 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change in body weight from baselineTime frame: 26 weeks
  2. Achieved Weight Loss ≥ 5% From BaselineTime frame: 26 weeks

Locations

62 sites in 7 countries. Site status is shown where the registry gives one.

  • Research Site

    Chandler, Arizona

  • Research Site

    Huntington Park, California

  • Research Site

    La Mesa, California

  • Research Site

    Lincoln, California

  • Research Site

    Walnut Creek, California

  • Research Site

    Hialeah, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Lombard, Illinois

  • Research Site

    Valparaiso, Indiana

  • Research Site

    West Des Moines, Iowa

  • Research Site

    Roslindale, Massachusetts

  • Research Site

    Farmington Hills, Michigan

  • Research Site

    Chesterfield, Missouri

  • Research Site

    Omaha, Nebraska

  • Research Site

    Vestal, New York

  • Research Site

    Durham, North Carolina

  • Research Site

    Wilmington, North Carolina

  • Research Site

    Fargo, North Dakota

  • Research Site

    Beachwood, Ohio

  • Research Site

    Cincinnati, Ohio

  • Research Site

    North Charleston, South Carolina

  • Research Site

    Spartanburg, South Carolina

  • Research Site

    Knoxville, Tennessee

  • Research Site

    Austin, Texas

  • Research Site

    Dallas, Texas

  • Research Site

    Houston, Texas

  • Research Site

    Woodway, Texas

  • Research Site

    Ogden, Utah

  • Research Site

    Charlottesville, Virginia

  • Research Site

    Manassas, Virginia

  • Research Site

    Heidelberg, Australia

  • Research Site

    Merewether, Australia

  • Research Site

    St Albans, Australia

  • Research Site

    St Leonards, Australia

  • Research Site

    Calgary, Alberta, Canada

  • Research Site

    Surrey, British Columbia, Canada

  • Research Site

    Victoria, British Columbia, Canada

  • Research Site

    Halifax, Nova Scotia, Canada

  • Research Site

    Guelph, Ontario, Canada

  • Research Site

    Hamilton, Ontario, Canada

Showing 40 of 62 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.